Cell Cure Neurosciences, a fully owned subsidiary of BioTime, Inc., was founded on cutting-edge technology from Hadassah University Hospital’s Human Embryonic Stem Cell Research Center and the Departments of Ophthalmology and Neurology. Cell Cure’s leading product, OpRegen, is in a Phase I/IIa clinical trial in patients with dry AMD. In addition, Cell Cure does research and development activities for other novel therapeutics based on embryonic stem cells and GMP production of cell-based products, including OpRegen. Cell Cure is located on the campus of Hadassah University Hospital in Jerusalem, Israel.
Dr. Rami Skaliter joined Cell Cure Neurosciences as Chief Executive Officer in June 2017. In his last position, Dr. Skaliter worked for ten years as the COO of Quark Pharmaceuticals, a late-stage pharmaceutical company developing siRNA-based novel therapeutics. Previously, Dr. Skaliter held various corporate and research executive positions at Quark Pharmaceuticals. Dr. Skaliter obtained his B.Sc. in Biology at the Ben-Gurion University and his M.Sc. and Ph.D. in Biochemistry at the Weizmann Institute in Israel. He specialized in the biochemistry of replication and mutagenesis mechanisms. Between 1993 and 1995, prior to joining Quark, Dr. Skaliter completed a post-doctoral fellowship at Stanford University. Dr. Skaliter serves as a director of Tikcro Technologies Ltd., a public company developing therapeutic antibodies.
Professor Reubinoff does research that is focused on human embryonic stem cells (hESCs). He derived hESC in collaboration with scientists from Monash University in Melbourne and the National University of Singapore. The group was the second in the world to derive hESC lines and was the first to show somatic differentiation of the hESCs in cultures.
Professor Banin is a key advisor at Cell Cure Neurosciences. He is the head of research into the degenerative diseases of the retina and macula, and an expert in the ﬁeld of cell therapy for those conditions.
Moshe Hukaylo, CPA, MBA, serves as the company’s CFO. He has more than 20 years of experience in finance, 15 years from within the pharmaceutical industry (Pfizer, Mercksrono). He has experience in all aspects of the pharmaceutical industry, including: biotech manufacturing, research and development, and sales and marketing. Moshe is the founder of On-Demand-CFO, a financial services consulting firm.
Osnat Bohana-Kashtan serves as the Director of Research and Development at Cell Cure Neurosciences. She holds a Ph.D. in Cell and Developmental Biology from Tel Aviv University and an M.B.A. from the College of Management, Rishon Le’zion. Prior to joining Cell Cure, she served as a leading scientist at Dynamix Pharmaceuticals, a pharmaceutical company focused on the discovery and development of novel small molecule drugs that target autoimmune diseases and cancer metabolism. Dr. Bohana-Kashtan underwent extensive post-doctoral training at the Johns Hopkins School of Medicine in the fields of stem cell biology and the immunology of allogeneic transplantation.
Nir Netzer joined Cell Cure in 2012 and serves as the Director of Operations. He is responsible for the company’s operation, including the construction of Cell Cure’s new GMP facility for the production of clinical grade OpRegen. Previously, Dr. Netzer served as Cell Cure’s Preclinical Studies Manager and led the company’s IND enabling studies that serve as the basis for the ongoing clinical development of OpRegen in treating dry AMD. Prior to joining Cell Cure, Dr. Netzer served as a basic Science and Preclinical Studies Manager at Pluristem Ltd. Dr. Netzer received his Ph.D. in Biotechnology from the Technion (Haifa, Israel), and was a postdoctoral fellow at the NIAID/NIH, where he studied viral immunology.
Maria Gurevich has been our Director of Clinical Affairs since 2015 and is responsible for the clinical activities of our company. She has more than 20 years of experience in the pharmaceutical industry in various capacities. She was previously with Quintiles as the Global Feasibility Manager, where she was responsible for assessing new business opportunities and developing an operational strategy based on data driven analysis. Previously, Maria was with Teva Pharmaceutical Industries as a Clinical Development Manager in Global R&D, where she was responsible for the planning and management of global clinical trials across several indications from phase II to regulatory submissions.
Sara Altman has been our company’s Finance Manager since 2011. She has extensive finance experience, which includes preparing financial reports and budgets, and taking responsibility for the grants our company receives. She previously served as a Senior CPA at Ziv Haft Deri (BDO) and was responsible for auditing the company’s financial statements. Sara is a licensed CPA and holds a B.A. in Accounting and Information Systems from Lev Academic Center and an M.A. in Accounting from Bar Ilan University.